Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

NCT03685630 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.

NCT NCT03685630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03685630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Lead sponsor
UCB Biopharma S.P.R.L.
Phase
Phase 3
Overall status
Completed
Start date
January 4, 2019
Completion date
March 27, 2021
Enrollment
10 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, partial seizures with or without secondary generalization